Our Programs

Pipeline

Our ambition is prevention and cure. Our universal technology can be used in prophylaxis or therapy. It is based on a patent-protected family of engineered viruses, which naturally elicit neutralizing antibodies and extremely potent T cell responses. The efficacy of our TheraT® and Vaxwave® platforms are being tested all across our pipeline.

Program
Vector
Target
DiscoveryDisc.
Pre-ClinicalPre.
Phase1Ph1.
Phase2Ph2.
Phase3Ph3.
HB-101
VaxWave® / LCMV _ gB/pp65
HBV Therapy - Gilead collaboration
Undisclosed
HIV Therapy - Gilead collaboration
Undisclosed
HB-202
TheraT® / LCMV&PIC _ E7/E6
HB-301
TheraT® / LCMV&PIC _ PAP/PSA/PSMA
To be Defined
Next Generation Antigen
Shared Neoantigen
Infectious
Oncology